Overview

A Phase 2 Study With CC-220 in Skin Sarcoidosis

Status:
Withdrawn

Trial end date:
2017-06-30

Target enrollment:

Participant gender:

Summary

This study will evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of oral CC-220 in adult subjects with chronic cutaneous sarcoidosis.

Phase:

Phase 2

Details

Lead Sponsor:

Celgene
Celgene Corporation